Kairos Pharma Receives Clinical Trials Arena Research and Development Award for Advanced Prostate Cancer Treatment

Kairos Pharma Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on cancer therapeutics, has been named a winner of the 2025 Clinical Trials Arena Excellence Awards, receiving the Research and Development Award for Advanced Prostate Cancer. The recognition highlights the Company’s work advancing ENV-105 (carotuximab), a first-in-class CD105-targeting monoclonal antibody being developed to address treatment resistance in metastatic castration-resistant prostate cancer, including positive interim safety and efficacy results from a Phase 2 randomized clinical trial evaluating ENV-105 in combination with apalutamide.

The award underscores the significance of Kairos Pharma's approach to overcoming one of the most challenging aspects of cancer treatment: drug resistance. The company's lead candidate, ENV-105, targets CD105, a protein identified as a key driver of resistance to various cancer treatments. Elevation of CD105 in response to standard therapy results in resistance and disease relapse. ENV-105 aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types.

Currently, ENV-105 is in a Phase 2 clinical trial for castrate-resistant prostate cancer and a Phase 1 trial for lung cancer aimed at addressing significant unmet medical needs. The Clinical Trials Arena Excellence Awards recognition validates the potential of this therapeutic approach at a critical juncture in the drug's development pathway. For investors and the medical community, this award serves as an external validation of the scientific merit and clinical promise of Kairos Pharma's research direction.

The positive interim results from the Phase 2 trial represent a meaningful step forward in a therapeutic area where new treatment options are urgently needed. Metastatic castration-resistant prostate cancer remains a difficult-to-treat condition with limited effective options after initial therapies fail. The combination approach being studied—ENV-105 with apalutamide—addresses the dual challenge of targeting the cancer while overcoming the resistance mechanisms that often render subsequent treatments ineffective.

This recognition comes at a time when the field of oncology is increasingly focused on overcoming treatment resistance, which represents a major barrier to long-term cancer management. The award highlights Kairos Pharma's position at the forefront of this important research area. The company's utilization of structural biology to overcome drug resistance and immune suppression in cancer represents a sophisticated approach to therapeutic development that is gaining attention within the scientific community.

For those following the company's progress, additional information and updates relating to KAPA are available through various channels. The latest news and updates relating to KAPA are available in the company’s newsroom at https://ibn.fm/KAPA. The broader context of this announcement is part of specialized financial communications through platforms like InvestorWire, which operates as part of the Dynamic Brand Portfolio that delivers advanced wire-grade press release syndication for private and public companies and the investment community. More information about these communications services is available at https://www.InvestorWire.com.